Calcitonin gene-related peptide in patients with and without early reperfusion after acute myocardial infarction.
Plasma concentrations of calcitonin gene-related peptide (CGRP), a potent regulator of vascular tone, creatine kinase, myoglobin, and cardiac troponin T were assessed in 31 patients with acute myocardial infarction. In patients who had sustained acute myocardial infarctions, maximum CGRP concentrations (median, 3.2 pmol/L; interquartile range, 1.5 to 4.8 pmol/L) were markedly elevated as compared with healthy control subjects (n = 23; median, 1.02 pmol/L; p = 0.02). However, no marked differences in CGRP levels were observed between patients with early reperfusion (n = 19; median, 3.5 pmol/L) and patients without early reperfusion (n = 12; median, 2.6 pmol/L; p = 0.96), as well as between those with congestive heart failure (n = 8; median, 3.9 pmol/L) and those without congestive heart failure (n = 23; median, 3.2 pmol/L; p = 0.62). CGRP did not correlate closely with myocardial protein release or hemodynamic parameters (heart rate and blood pressure) or the occurrence of arrhythmias. Therefore we conclude that elevated peripheral venous CGRP concentrations in patients who have sustained an acute myocardial infarction are independent of successful reperfusion and hemodynamic state. Although the cause of CGRP increase is not yet identified, CGRP may play a role in the regulation of coronary vascular tone in patients after acute myocardial infarction.
Lechleitner
P
P
Department of Internal Medicine, University of Innsbruck, Austria.
Genser
N
N
Mair
J
J
Dienstl
A
A
Haring
C
C
Wiedermann
C J
CJ
Puschendorf
B
B
Saria
A
A
Dienstl
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015740:Calcitonin Gene-Related Peptide / Q000097:blood*; D016022:Case-Control Studies; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D009211:Myoglobin / Q000097:blood; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013997:Time Factors; D014336:Troponin / Q000097:blood; D020107:Troponin T; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D009211:Myoglobin; D014336:Troponin; D020107:Troponin T; D003402:Creatine Kinase; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator; D015740:Calcitonin Gene-Related Peptide